13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0000882095
Total reported value
$1.6B
$1.6B
9 檔
104.1%
In Q3 2025, Gilead Sciences, Inc.'s U.S. equity holdings reached a combined market value of $1.6B, distributed across 9 disclosed stock positions.
In Q3 2025, Gilead Sciences, Inc. adopted a defensive or profit-taking posture, trimming 0 positions and completely liquidating 5 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including LKFT, ACLXGBX, RCUS) accounted for 104.1% of total reported equity market value during Q3 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 32.31% | +6.67% | — | |
| 2 | ACLXGBX | Arcellx Inc | Stock-Other | 30.80% | -36.44% | EXIT | |
| 3 | RCUS | Arcus Biosciences Inc | Stock-Other | 23.86% | +26.71% | — | |
| 4 | ASMB | Assembly Biosciences Inc | Stock-Other | 6.44% | +2.40% | +103.91% | |
| 5 | ✓ | Merus N V | Stock-Other | 2.38% | — | — | |
| 6 | TNGX | Tango Therapeutics Inc | Stock-Other | 2.28% | — | — | |
| 7 | KYTX | Kyverna Therapeutics Inc | Stock-Other | 1.38% | +0.55% | — | |
| 8 | ✓ | Xilio Therapeutics Inc | Stock-Other | 0.43% | +0.12% | — | |
| 9 | CYPH | Cypherpunk Technologies Inc | Stock-Other | 0.13% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ASMB | Assembly Biosciences Inc | +4.7% | +103.91% | Add |
| 2 | RCUS | Arcus Biosciences Inc | +3% | — | Unchanged |
| 3 | TNGX | Tango Therapeutics Inc | +1.7% | — | Unchanged |
| 4 | ✓ | Merus N V | +0.8% | — | Unchanged |
| 5 | KYTX | Kyverna Therapeutics Inc | +0.7% | — | Unchanged |
| 6 | CYPH | Cypherpunk Technologies Inc | 0% | — | Unchanged |
| 7 | ✓ | Xilio Therapeutics Inc | -0.1% | — | Unchanged |
| 8 | LKFT | Lakefront Biotherapeutic-adr | -3.2% | — | Unchanged |
| 9 | ACLXGBX | Arcellx Inc | -6.5% | — | Unchanged |
| 10 | KLRS | Kalaris Therapeutics Inc | — | EXIT | Sold out |
| 11 | ✓ | — | EXIT | Sold out | |
| 12 | ALLO | Allogene Therapeutics Inc | — | EXIT | Sold out |
| 13 | ✓ | Ikena Oncology Inc | — | EXIT | Sold out |
| 14 | BRNS | Barinthus Biotherapeutics Pl | — | EXIT | Sold out |
According to official SEC Form 13F filings, Gilead Sciences, Inc. reported a total U.S. public equity portfolio value of $1.6B across 9 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top Position Liquidated / Trimmed
KLRS
前期市值: $5.8M
During Q3 2025, Gilead Sciences, Inc.'s top holdings by market value included LKFT (32.3%)、ACLXGBX (30.8%)、RCUS (23.9%). The largest single position, LKFT, represented 32.3% of total portfolio value.
In Q3 2025, Gilead Sciences, Inc. made 6 total portfolio adjustments, initiating 0 new buys, adding to 1 positions, trimming 0 holdings, and fully liquidating 5 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.